Logo image of TNON

TENON MEDICAL INC (TNON) Stock Fundamental Analysis

USA - NASDAQ:TNON - US88066N3035 - Common Stock

1.23 USD
+0.01 (+0.82%)
Last: 10/3/2025, 8:07:56 PM
1.19 USD
-0.04 (-3.25%)
Pre-Market: 10/6/2025, 7:33:41 AM
Fundamental Rating

3

TNON gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. TNON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, TNON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year TNON has reported negative net income.
In the past year TNON has reported a negative cash flow from operations.
In the past 5 years TNON always reported negative net income.
In the past 5 years TNON always reported negative operating cash flow.
TNON Yearly Net Income VS EBIT VS OCF VS FCFTNON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

TNON's Return On Assets of -113.87% is on the low side compared to the rest of the industry. TNON is outperformed by 79.06% of its industry peers.
Looking at the Return On Equity, with a value of -188.53%, TNON is doing worse than 70.68% of the companies in the same industry.
Industry RankSector Rank
ROA -113.87%
ROE -188.53%
ROIC N/A
ROA(3y)-185.03%
ROA(5y)-156.48%
ROE(3y)-844.8%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TNON Yearly ROA, ROE, ROICTNON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

With a Gross Margin value of 45.44%, TNON perfoms like the industry average, outperforming 40.31% of the companies in the same industry.
TNON's Gross Margin has declined in the last couple of years.
TNON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.76%
GM growth 5Y-8.18%
TNON Yearly Profit, Operating, Gross MarginsTNON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

6

2. Health

2.1 Basic Checks

TNON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNON has been increased compared to 1 year ago.
Compared to 5 years ago, TNON has more shares outstanding
There is no outstanding debt for TNON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TNON Yearly Shares OutstandingTNON Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M
TNON Yearly Total Debt VS Total AssetsTNON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -10.80, we must say that TNON is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -10.80, TNON is not doing good in the industry: 80.63% of the companies in the same industry are doing better.
TNON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.8
ROIC/WACCN/A
WACC8.52%
TNON Yearly LT Debt VS Equity VS FCFTNON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

TNON has a Current Ratio of 3.86. This indicates that TNON is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.86, TNON is doing good in the industry, outperforming 68.06% of the companies in the same industry.
TNON has a Quick Ratio of 3.59. This indicates that TNON is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TNON (3.59) is better than 71.73% of its industry peers.
Industry RankSector Rank
Current Ratio 3.86
Quick Ratio 3.59
TNON Yearly Current Assets VS Current LiabilitesTNON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

6

3. Growth

3.1 Past

TNON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.63%, which is quite impressive.
TNON shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.60%.
The Revenue has been growing by 130.83% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)78.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.59%
Revenue 1Y (TTM)-12.6%
Revenue growth 3Y173.6%
Revenue growth 5Y130.83%
Sales Q2Q%-37.4%

3.2 Future

Based on estimates for the next years, TNON will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.89% on average per year.
The Revenue is expected to grow by 66.32% on average over the next years. This is a very strong growth
EPS Next Y92.39%
EPS Next 2Y40.08%
EPS Next 3Y25.55%
EPS Next 5Y14.89%
Revenue Next Year24.48%
Revenue Next 2Y50.58%
Revenue Next 3Y64.91%
Revenue Next 5Y66.32%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TNON Yearly Revenue VS EstimatesTNON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M
TNON Yearly EPS VS EstimatesTNON Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNON. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNON Price Earnings VS Forward Price EarningsTNON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNON Per share dataTNON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as TNON's earnings are expected to grow with 25.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.08%
EPS Next 3Y25.55%

0

5. Dividend

5.1 Amount

TNON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

TENON MEDICAL INC

NASDAQ:TNON (10/3/2025, 8:07:56 PM)

Premarket: 1.19 -0.04 (-3.25%)

1.23

+0.01 (+0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners1.48%
Inst Owner Change0%
Ins Owners3.35%
Ins Owner Change0%
Market Cap10.58M
Analysts82.5
Price Target2.93 (138.21%)
Short Float %7.21%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.85%
Min EPS beat(2)10.79%
Max EPS beat(2)24.91%
EPS beat(4)4
Avg EPS beat(4)13.41%
Min EPS beat(4)1.96%
Max EPS beat(4)24.91%
EPS beat(8)8
Avg EPS beat(8)21.32%
EPS beat(12)11
Avg EPS beat(12)17.92%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-39.92%
Min Revenue beat(2)-40.64%
Max Revenue beat(2)-39.2%
Revenue beat(4)0
Avg Revenue beat(4)-38.69%
Min Revenue beat(4)-47.97%
Max Revenue beat(4)-26.94%
Revenue beat(8)0
Avg Revenue beat(8)-25.84%
Revenue beat(12)0
Avg Revenue beat(12)-22.46%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-51.41%
PT rev (3m)-50.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)39.85%
EPS NY rev (1m)0%
EPS NY rev (3m)31.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.59
P/FCF N/A
P/OCF N/A
P/B 1.58
P/tB 1.58
EV/EBITDA N/A
EPS(TTM)-7.54
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-1.17
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0.34
BVpS0.78
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -113.87%
ROE -188.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.44%
FCFM N/A
ROA(3y)-185.03%
ROA(5y)-156.48%
ROE(3y)-844.8%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.76%
GM growth 5Y-8.18%
F-Score4
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.76%
Cap/Sales 8.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.86
Quick Ratio 3.59
Altman-Z -10.8
F-Score4
WACC8.52%
ROIC/WACCN/A
Cap/Depr(3y)391.88%
Cap/Depr(5y)N/A
Cap/Sales(3y)47.06%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.59%
EPS Next Y92.39%
EPS Next 2Y40.08%
EPS Next 3Y25.55%
EPS Next 5Y14.89%
Revenue 1Y (TTM)-12.6%
Revenue growth 3Y173.6%
Revenue growth 5Y130.83%
Sales Q2Q%-37.4%
Revenue Next Year24.48%
Revenue Next 2Y50.58%
Revenue Next 3Y64.91%
Revenue Next 5Y66.32%
EBIT growth 1Y7.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.55%
OCF growth 3YN/A
OCF growth 5YN/A